Precision radiopharmaceuticals for cancer treatment
PRECIRIX® is a clinical-stage biotechnology company dedicated to improving the lives of cancer patients by developing novel targeted radiopharmaceuticals using camelid single domain antibody fragments.
The company is advancing its lead product CAM-H2 through a Phase I/II clinical trial targeting HER2-positive tumors, while further progressing and broadening its oncology pipeline.
PRECIRIX' technology platform allows for a theranostic approach, using the same molecule for patient selection (imaging) and therapy.
Join our team
At Precirix we care about people. We strive to improve the lives of cancer patients by developing novel radiopharmaceuticals that address unmet medical needs. We bring together a unique and varied set of talents to accomplish this goal. If you are interested in joining our multidisciplinary team, look into our vacancies or send your spontaneous application to firstname.lastname@example.org.
Your browser is not supported. Update your browser for more security, speed and to make the most of this site.